Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
about
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin AmyloidosisNatural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugsAβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and function.Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent ConjugateAG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretinThermodynamic Stabilization of the Folded Domain of Prion Protein Inhibits Prion Infection in VivoA Nanobody Binding to Non-Amyloidogenic Regions of the Protein Human Lysozyme Enhances Partial Unfolding but Inhibits Amyloid Fibril FormationFluorogenic small molecules requiring reaction with a specific protein to create a fluorescent conjugate for biological imaging-what we know and what we need to learnProteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesisStructural evidence for asymmetric ligand binding to transthyretinSmall-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) InterfaceProtein stability: a crystallographer's perspectiveFirst European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathyEngineering enhanced protein disaggregases for neurodegenerative diseaseEndoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside outTargeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's diseaseThe flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic responseTetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin TetramerIdentification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for TauopathiesMolecular basis of classic galactosemia from the structure of human galactose 1-phosphate uridylyltransferase.Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis.Designed Trpzip-3 β-Hairpin Inhibits Amyloid Formation in Two Different Amyloid SystemsInhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel.Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trialRoom-temperature palladium-catalyzed direct 2-arylation of benzoxazoles with aryl and heteroaryl bromides.Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis.Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case.Novel drugs targeting transthyretin amyloidosis.FAP neuropathy and emerging treatments.Specific aromatic foldamers potently inhibit spontaneous and seeded Aβ42 and Aβ43 fibril assembly.Recent progress in the understanding and treatment of transthyretin amyloidosis.Surface effects mediate self-assembly of amyloid-β peptides.Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy.An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.ATF6 activation reduces the secretion and extracellular aggregation of destabilized variants of an amyloidogenic protein.Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis.Structure-based analysis of A19D, a variant of transthyretin involved in familial amyloid cardiomyopathy.Identification and characterization of a compound from Cuminum cyminum essential oil with antifibrilation and cytotoxic effectModulating inhibitors of transthyretin fibrillogenesis via sulfation: polychlorinated biphenyl sulfates as models.
P2860
Q26764754-26E9FF9A-D1C1-46E0-98AD-B750586EA6F8Q27009309-7C40C3CB-3C72-470C-B2BE-5EA96F87C3ECQ27308119-5EEBB384-5F05-4B20-B495-764DF0B1ACCAQ27675997-0766FCCD-2736-4C1E-9E9D-8001D3772BA7Q27678369-9168F6B4-4B4D-4286-9A08-3FE7E90849A9Q27679150-A464921B-CF20-4127-9CCF-CE6AE938CB48Q27679384-5427075B-3F8B-4537-A85D-15E68A815CE8Q27680199-89115419-51C0-4923-941C-99B673AAEDCBQ27681502-D2F60EC9-658C-45D4-9600-33FEDE667811Q27701741-9445D4FD-E70D-4738-AAA6-517C1AABF017Q27703111-AC69E4F6-9BA6-4D62-AC54-759D7F260542Q28068775-E202A16A-3C4C-4425-80CD-D169D15950A5Q28071522-0232355B-A487-4E42-BDEA-55E1E794A813Q28083809-3412B478-97C5-41B7-8B1B-A4FFE29B9193Q28084013-45B1F9C8-20EF-4A9C-B686-9A48220842D2Q28539839-A33A638B-1F1B-4CA1-9C4C-AFBFC4A79C1FQ28547541-EAED93AF-4DD7-40A5-AC86-C77ADAAF6619Q28551432-591B4872-109D-449E-B681-C09718BA1ACAQ28597211-A5A1379C-2C57-46E0-A274-DF9E38097CFDQ30668563-33F253A8-662F-458D-8CB8-8DA4CD6E933DQ33423160-0FDE154C-36BF-4500-8799-266B0E4C7729Q33635955-3329ED74-56A1-4778-A426-2184EEC5F26DQ33671132-25EC07A5-6873-4ABB-B1C6-8FC09B41AE4FQ33903527-BC9AB42A-3E96-4DA1-85F0-2D7E18360F8EQ34105124-CB44C294-6829-4038-BC7B-20C9CB169250Q34336131-05389803-E945-4B28-971D-E9D514CF0B01Q34379670-B0AAE9F3-D0D5-4DB1-9293-3EE30A57D095Q34400138-000DB8A3-5E23-408E-9185-6FC6D1DFD7C2Q34401190-6311409A-525E-473C-80A4-3D4E6B886B3FQ34402886-07A77620-C29F-4589-9DED-FEB6F4571FADQ34416193-E9575ABC-9F3B-4845-AA57-770AE3EAC35CQ34419863-D61934C4-5CF9-485A-9D99-10681568325EQ34422510-5EFB8E36-976F-47C8-8E42-CE4245F35EECQ34428314-41B53C58-D45A-45C9-A3B5-9C219C73FB77Q34625989-8B70FD3D-3886-4E0E-94D0-689F058FC8AFQ34838524-32D543C7-3B45-48EB-9894-ADDB419DA8ECQ34923990-7E0252FA-3B6D-45DA-8067-65BB42FB1D7DQ35072784-F4A0AA35-FEF8-4478-B134-7FE3F95998C8Q35080748-603C5B5E-73E8-4A4D-B2D7-59EF10116F79Q35082885-D1B2D7B2-51AA-4313-A873-4AB5EF852535
P2860
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Tafamidis, a potent and select ...... t inhibits the amyloid cascade
@ast
Tafamidis, a potent and select ...... t inhibits the amyloid cascade
@en
Tafamidis, a potent and select ...... t inhibits the amyloid cascade
@nl
type
label
Tafamidis, a potent and select ...... t inhibits the amyloid cascade
@ast
Tafamidis, a potent and select ...... t inhibits the amyloid cascade
@en
Tafamidis, a potent and select ...... t inhibits the amyloid cascade
@nl
prefLabel
Tafamidis, a potent and select ...... t inhibits the amyloid cascade
@ast
Tafamidis, a potent and select ...... t inhibits the amyloid cascade
@en
Tafamidis, a potent and select ...... t inhibits the amyloid cascade
@nl
P2093
P2860
P50
P3181
P356
P1476
Tafamidis, a potent and select ...... t inhibits the amyloid cascade
@en
P2093
Charlotte Weigel
Christine E Bulawa
James A Fleming
Jeff Packman
Michael Devit
R Luke Wiseman
Stephen Connelly
Theodore R Foss
P2860
P304
P3181
P356
10.1073/PNAS.1121005109
P407
P577
2012-06-12T00:00:00Z